AN UNBIASED VIEW OF AGO TUMOR

Special pathological reporting is essential in clients undergoing neoadjuvant systemic therapy (NST). There exist a minimum of 5 unique reporting scores for the quality of remission right after NST; Many of these, however, are only validated for inflammatory breast cancer (e.This investigation or therapeutic intervention is of confined benefit for